Trial Profile

Real World Study Comparing Incidence of Thromboembolic Events in Patients of Polycythemia Vera Treated with Hydroxyurea (HU) and Switched to Ruxolitinib

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
05 Dec 2019 New trial record
06 Nov 2019 Results, comparing the incidence of Thromboembolic events in hydroxyurea -treated polycythemia vera patients who switched to ruxolitinib after initial treatment hydroxyurea or continued hydroxyurea without switching with the help of OPTUM database, released at the 61st Annual Meeting and Exposition of the American Society of Hematology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com